Stocksigma LogoStocksigma Logo

Sun Pharma Receives 'AAA/Stable' Ratings for INR 15,000 Crore NCD Issue

On 13th Oct'26, CRISIL and ICRA assigned 'AAA/Stable' ratings to Sun Pharma's proposed INR 15,000 crore NCD programme and reaffirmed 'A1+' on its INR 4,000

Sun Pharma Receives 'AAA/Stable' Ratings for INR 15,000 Crore NCD Issue

Sun Pharmaceutical Industries Ltd · Others (Uncategorized) · 13 Oct 2026, 11:23 pm

Sun Pharma Receives 'AAA/Stable' Ratings for INR 15,000 Crore NCD Issue On 13th Oct'26, CRISIL and ICRA assigned 'AAA/Stable' ratings to Sun Pharma's proposed INR 15,000 crore NCD programme and reaffirmed 'A1+' on its INR 4,000 crore CP facility. The ratings factor in the proposed USD 11.75 billion acquisition of Organon & Co. Net debt to EBITDA is projected to rise temporarily to 1.5–2.0x in FY28 before deleveraging. In Q1 FY27, operating income rose ~10% YoY to INR 15,300 crore with a 29% operating margin, backed by strong growth in India and innovative medicines.

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements